Healthcare Equities

The companies that provide, support or coordinate medical goods and services. This sector spans a broad range of activities – including the development and manufacture of medical equipment, pharmaceuticals and other treatments. Activities range from research to manufacturing, administration, insurance and facilities management. Our Healthcare research includes healthcare services, healthcare information technology (IT), medical devices, biotechnology, biopharmaceuticals and specialty pharmaceuticals.

SIGA Technologies (Nasdaq: SIGA) expands portfolio with new preclinical monoclonal antibody programme >

Jyoti Prakash | Healthcare | Comment | 1 day ago

SIGA Technologies (Nasdaq: SIGA) expands portfolio with new preclinical monoclonal antibody programme >

Jyoti Prakash | Healthcare | Comment | 1 day ago

SEE ALL COMMENTARY >

Actinogen Medical (ACW)

Latest price

AUD0.03

— 0.00 (3.85)

As at 22/10/2024

Market capitalisation: AUD80m

View equity

Update

Healthcare

15.10.24

Actinogen Medical — A$11.1m capital raise completed

Update

Healthcare

07.10.24

Actinogen Medical — Funding in place to complete XanaMIA Phase IIb

Flash note

Healthcare

27.08.24

NZD3.32

▾ −0.03 (−0.90)

As at 22/10/2024

Market capitalisation: NZD339m

View equity

Flash note

Healthcare

30.09.24

AFT Pharmaceuticals — Maxigesic IV reaches the Chinese shores

edison tv

Healthcare

26.09.24

AFT Pharmaceuticals – executive interview

Flash note

Healthcare

09.08.24

GBP0.20

— 0.00 (0.00)

As at 22/10/2024

Market capitalisation: GBP13m

View equity

Update

Healthcare

14.10.24

Argent Biopharma — Valuation report

QuickView

Healthcare

05.09.24

Argent Biopharma — An innovative approach to drug development

Update

Healthcare

04.11.19

CHF44.40

▾ −0.60 (−1.33)

As at 22/10/2024

Market capitalisation: CHF601m

View equity

Flash note

Healthcare

11.10.24

Basilea Pharmaceutica — Milestone march continues for Cresemba

Update

Healthcare

24.09.24

Basilea Pharmaceutica — BARDA backs Basilea’s anti-infectives programme

Flash note

Healthcare

09.09.24

SEK3.07

▾ 0.07 (2.33)

As at 22/10/2024

Market capitalisation: SEK548m

View equity

Flash note

Healthcare

19.04.23

Cantargia — Encouraging data for nadunolimab in CANFOUR

Flash note

Healthcare

14.03.23

Cantargia — First patient treated in Phase II part of TRIFOUR

Update

Healthcare

27.02.23

SEK5.39

▾ −0.06 (−1.10)

As at 22/10/2024

Market capitalisation: SEK1,490m

View equity

edison tv

Healthcare

07.10.24

Cereno Scientific – executive interview

Update

Healthcare

02.10.24

Cereno Scientific — CS1 shines in Phase IIa PAH trial

Flash note

Healthcare

04.09.24

SEK0.94

▾ 0.34 (56.67)

As at 22/10/2024

Market capitalisation: SEK57m

View equity

thematic

Healthcare

04.01.24

Outlook for 2024: Life sciences – where has the conviction gone?

Update

Healthcare

02.06.23

Chosa Oncology — Making headway in precision oncology

Update

Healthcare

28.02.22

GBP0.20

— 0.00 (0.00)

As at 22/10/2024

Market capitalisation: GBP74m

View equity

Flash note

Healthcare

19.09.24

Creo Medical — Consumables business divested in strategic move

Flash note

Healthcare

05.07.24

Creo Medical — Intuitive deal expansion is a notable milestone

edison tv

Healthcare

04.06.24

USD1.65

▾ 0.05 (3.13)

As at 22/10/2024

Market capitalisation: USD48m

View equity

Flash note

Healthcare

04.10.24

Immix Biopharma — US CAR-T trial progresses to dose expansion

Update

Healthcare

14.08.24

Immix Biopharma — Full steam ahead with US CAR-T trial

Flash note

Healthcare

29.07.24

SEK11.90

▾ −0.30 (−2.46)

As at 22/10/2024

Market capitalisation: SEK648m

View equity

Flash note

Healthcare

08.10.24

IRLAB Therapeutics — IRL757 progress prompts $2.5m milestone payment

Flash note

Healthcare

03.10.24

IRLAB Therapeutics — IRL757 starts strong in Phase I

Flash note

Healthcare

01.10.24

EUR1.84

▾ −0.08 (−4.38)

As at 22/10/2024

Market capitalisation: EUR28m

View equity

edison tv

Healthcare

30.09.24

SEK8.00

▾ −0.19 (−2.32)

As at 22/10/2024

Market capitalisation: SEK413m

View equity

Update

Healthcare

27.08.24

Mendus — Broad progress across the pipeline

edison tv

Industrials

23.08.24

Mendus – executive interview

Flash note

Healthcare

24.07.24

USD6.31

▾ −0.17 (−2.62)

As at 22/10/2024

Market capitalisation: USD485m

View equity

thematic

Healthcare

04.01.24

Outlook for 2024: Life sciences – where has the conviction gone?

edison tv

Healthcare

20.04.23

MindMed update on major depressive disorder data: Rob Barrow, CEO

edison tv

Healthcare

29.03.23

CHF9.00

▾ 0.04 (0.45)

As at 22/10/2024

Market capitalisation: CHF172m

View equity

Update

Healthcare

23.09.24

Newron Pharmaceuticals — Moving full steam towards pivotal studies

Flash note

Healthcare

26.06.24

Newron Pharmaceuticals — Evenamide road to registration and beyond

Flash note

Healthcare

14.05.24

EUR0.26

▾ −0.01 (−2.23)

As at 22/10/2024

Market capitalisation: EUR18m

View equity

Flash note

Healthcare

18.12.23

Nicox — Animal data show favourable profile vs Lumigan

Update

Healthcare

14.11.23

Nicox — Q323 update confirms trajectory for NCX-470

Flash note

Healthcare

21.07.23

USD1.71

▾ −0.04 (−2.29)

As at 22/10/2024

Market capitalisation: USD15m

View equity

Update

Healthcare

14.08.23

OpGen — Cash concerns dampen active Q2

Flash note

Healthcare

04.08.23

OpGen — FIND collaboration advances to development

Flash note

Healthcare

21.07.23

OpGen — Feasibility milestone from FIND collaboration

See more
content on

OpGen

Equities

Equities by Sector

Sectors

Thematics

Latest

A net zero perspective – Investing in sustainability, technology & innovation

Banco Angolano de Investimentos (BAI) – Money-centre bank with lending optionality

The art of measurement – Challenges in metrology

Audiovisual

Latest

SenSen Networks – executive interview

Deep dive into artificial intelligence interview: Northern Data Group

BB Biotech – executive interview

About Edison

About Edison

Careers

Healthcare Equities

Actinogen Medical (ACW)

AUD0.03

Actinogen Medical — A$11.1m capital raise completed

Actinogen Medical — Funding in place to complete XanaMIA Phase IIb

Actinogen Medical — Further positive XanaCIDD results on depression

See morecontent on

AFT Pharmaceuticals (AFT)

NZD3.32

AFT Pharmaceuticals — Maxigesic IV reaches the Chinese shores

AFT Pharmaceuticals – executive interview

AFT Pharmaceuticals — Hikma partnership expands to include Combogesic

See morecontent on

Argent Biopharma (RGT)

GBP0.20

Argent Biopharma — Valuation report

Argent Biopharma — An innovative approach to drug development

MGC Pharmaceuticals — Rapid prescription growth in Australia and the UK

See morecontent on

Basilea Pharmaceutica (BSLN)

CHF44.40

Basilea Pharmaceutica — Milestone march continues for Cresemba

Basilea Pharmaceutica — BARDA backs Basilea’s anti-infectives programme

Basilea Pharmaceutica — H2 rewards continue: US$25m Cresemba milestone

See morecontent on

Cantargia (CANTA)

SEK3.07

Cantargia — Encouraging data for nadunolimab in CANFOUR

Cantargia — First patient treated in Phase II part of TRIFOUR

Cantargia — Next phase of clinical development in sight

See morecontent on

Cereno Scientific (CRNO-B)

SEK5.39

Cereno Scientific – executive interview

Cereno Scientific — CS1 shines in Phase IIa PAH trial

Cereno Scientific — CS1 granted OMPD, complementing FDA ODD

See morecontent on

Chosa (CHOSA)

SEK0.94

Outlook for 2024: Life sciences – where has the conviction gone?

Chosa Oncology — Making headway in precision oncology

RhoVac — On the home straight

See morecontent on

Creo Medical (CREO)

GBP0.20

Creo Medical — Consumables business divested in strategic move

Creo Medical — Intuitive deal expansion is a notable milestone

Creo Medical – executive interview with Craig Gulliford, CEO

See morecontent on

Immix Biopharma (IMMX)

USD1.65

Immix Biopharma — US CAR-T trial progresses to dose expansion

Immix Biopharma — Full steam ahead with US CAR-T trial

Immix Biopharma — US$8m grant to advance novel CAR-T treatment

See morecontent on

IRLAB Therapeutics (IRLAB-A)

SEK11.90

IRLAB Therapeutics — IRL757 progress prompts $2.5m milestone payment

IRLAB Therapeutics — IRL757 starts strong in Phase I

IRLAB Therapeutics — Pirepemat Phase IIb trial completes enrolment

See morecontent on

Medigene (MDG1)

EUR1.84

Medigene – executive interview

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on